A Prospective, Randomized, Double-Blind, Parallel-Group, Comparative Effectiveness Clinical Trial Comparing a Powder Vehicle Compound of Vitamin D With an Oil Vehicle Compound in Adults With Cystic Fibrosis.

Wendy A. Hermes, Emory University
Jessica Alvarez, Emory University
Moon J. Lee, Emory University
Supavit Chesdachai, Emory University
Daud Lodin, Emory University
Ron Horst, Heartland Assays
Vin Tangpricha, Emory University

Journal Title: Journal of Parenteral and Enteral Nutrition
Publisher: SAGE Publications | 2016-02-22
Type of Work: Article | Post-print: After Peer Review
Publisher DOI: 10.1177/0148607116629673
Permanent URL: https://pid.emory.edu/ark:/25593/s4tfb

Final published version: http://dx.doi.org/10.1177/0148607116629673

Copyright information:
© 2016, © SAGE Publications

Accessed January 8, 2018 7:45 AM EST
A Prospective, Randomized, Double-Blind, Parallel-Group, Comparative Effectiveness Clinical Trial Comparing a Powder Vehicle Compound of Vitamin D With an Oil Vehicle Compound in Adults With Cystic Fibrosis

Wendy A. Hermes, MS, RD, LD¹, Jessica A. Alvarez, PhD, RD¹, Moon J. Lee, BS¹, Supavit Chesdachai, MD¹, Daud Lodin, MPH¹, Ron Horst, PhD³, and Vin Tangpricha, MD, PhD¹,²

¹Division of Endocrinology, Metabolism and Lipids, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
²Atlanta VA Medical Center, Decatur, Georgia, USA
³Heartland Assays, LLC, Ames, Iowa, USA

Abstract

Background—There is little consensus on the most efficacious vehicle substance for vitamin D supplements. Fat malabsorption may impede the ability of patients with cystic fibrosis (CF) to absorb vitamin D in an oil vehicle. We hypothesized that vitamin D contained in a powder vehicle would be absorbed more efficiently than vitamin D contained in an oil vehicle in patients with CF.

Methods—In this double-blind, randomized controlled trial, hospitalized adults with CF were given a one-time bolus dose of 100,000 IU of cholecalciferol (D₃) in a powder-based or oil-based vehicle. Serum D₃, 25-hydroxyvitamin D, and parathyroid hormone concentrations were analyzed at 0, 12, 24, and 48 hours posttreatment. The area under the curve for serum D₃ and the 12-hour time point were also assessed as indicators of D₃ absorption.

Results—This trial was completed by 15 patients with CF. The median (interquartile range) age, body mass index, and forced expiratory volume in 1 second were 23.7 (19.9–33.2) years, 19.9 (18.6–22.6) kg/m², and 63% (37%–80%), respectively. The increase in serum D₃ and the area under the curve was greater in the powder group (P = .002 and P = .036, respectively). Serum D₃ was higher at 12 hours in the powder group compared with the oil group (P = .002), although levels were similar between groups by 48 hours.
Conclusions—In adults with CF, cholecalciferol is more efficiently absorbed in a powder compared with an oil vehicle. Physicians should consider prescribing vitamin D in a powder vehicle in patients with CF to improve the absorption of vitamin D from supplements.

Keywords
cholecalciferol; ergocalciferol; vitamin D; cystic fibrosis; vitamin D₃; vehicle; pancreatic insufficiency; malabsorption

Introduction

Cystic fibrosis (CF) is a genetic disorder that prevents proper epithelial surface hydration in the lungs, pancreas, and other organs. Thickened mucus in the pancreas, in particular, induces acinar scarring and defective secretion of bicarbonate, which ultimately leads to exocrine pancreatic insufficiency. This, in turn, causes intestinal malabsorption of fat-soluble vitamins and chronic nutrient deficiencies of vitamins A, D, E, and K.₁ People with pancreatic insufficiency replace insufficient bicarbonate and enzymes with routine use of pancreatic enzyme replacement therapy (PERT), the dose of which is individual to the patient’s weight or per gram of fat intake in the diet. Despite the regular use of enzymes, fat absorption in CF often remains suboptimal.²,³ Vitamin D deficiency, in particular, is highly prevalent in patients with CF.⁴⁻⁸ In addition to its most well-defined roles in calcium homeostasis and bone maintenance, new studies in patients with CF present evidence that vitamin D plays a role in immunity and lung health.⁹,¹⁰ Achieving optimal vitamin D status is, therefore, an important component of CF care.

In 2012, the Cystic Fibrosis Foundation updated recommendations for vitamin D therapy in patients with CF, calling for higher doses of vitamin D to maintain optimal vitamin D status in adults and children with CF.⁷ However, there remains some question as to the most efficient vehicle compound for the vitamin D supplement for maximal absorption. A vehicle is a substance that may bind or carry the vitamin from one place to another and can include oils, water, or acidic-based substances. Vitamin D is a fat-soluble vitamin and is more efficiently absorbed when combined with fats/oils as the vehicle compound in healthy individuals.¹¹ Thus, most vitamin D pills marketed in the United States are formulated with a fat-soluble vehicle.¹¹,¹² Vitamin D deficiency is often incipient even in the face of vitamin D supplementation, and it is not known whether the oil-based vehicle substances of standard vitamin D supplements are poorly absorbed by patients with CF.¹¹⁻¹³ There have been no clinical trials conducted in the CF population to evaluate the impact of the vehicle substance on absorption of vitamin D. One 2007 pharmacokinetic trial in CF illustrated superior absorption of a water-soluble vitamin E supplement compared with oil.¹⁴ Since vitamin D supplements are produced in both water-miscible and oil-miscible forms, it is possible the vehicle may play a role in the success of vitamin D repletion in CF. The objective of this study is to determine whether oil or powder is a more effective vehicle of vitamin D₃ for patients with CF. Effectiveness was evaluated with serum cholecalciferol at 12 hours and the area under the curve (AUC). Based on the current understanding that fat is malabsorbed in CF, we hypothesized that a powder vehicle would support better overall absorption of vitamin D₃ in this population.
Materials and Methods

Patients

Study patients were at least 18 years old with a history of CF and were recruited from Emory University Hospital during an inpatient hospital admission for pulmonary exacerbation. Screening of new inpatients was completed daily by a research coordinator. Exclusion criteria included a history of disorders associated with hypercalcemia and/or current hypercalcemia (serum albumin corrected, serum calcium >10.8 mg/dL, or ionized calcium >5.2 mg/dL), chronic kidney disease worse than stage III (<60 mL/min), forced expiratory volume in 1 second (FEV1) predicted <20%, current significant hepatic dysfunction total bilirubin >2.5 mg/dL with direct bilirubin >1.0 mg/dL, inability to tolerate oral food or medications, current use of cytotoxic or immunosuppressive drugs, history of AIDS or illicit drug abuse, current or planned pregnancy within the following year, or current enrollment in another intervention trial. Clinical data were extracted from electronic medical health records and included age, sex, ethnicity, body mass index (BMI), comorbidities, antibiotic use, diabetes status, most recent serum 25-hydroxyvitamin D (25(OH)D), and FEV1 as a measure of lung function. Questionnaires were designed by the study team and used to assess current vitamin supplementation and enzyme use.

This study was approved by the Emory Institutional Review Board, and all patients provided written informed consent prior to study procedures. The trial was registered at clinicaltrial.gov as NCT01880346.

Intervention

Patients were randomized in blocks of 4 to powder-based or oil-based supplements containing a total amount of 100,000 IU of vitamin D₃ (cholecalciferol). The powder bolus, Vitamin D₃-50 Cholecalciferol, was obtained from BioTech Pharmacal (Fayetteville, AR) (50,000 IU of cholecalciferol/tablet; inactive ingredients: gelatin, lactose, cellulose, and magnesium stearate); patients received 2 tablets totaling 100,000 IU of cholecalciferol. The oil-based vitamin D₃ supplements were obtained from BTR Group (Pittsfield, IL) (Maximum D3; 10,000 IU of cholecalciferol/tablet, refined soybean oil, and glycerin); patients received 10 tablets totaling 100,000 IU of cholecalciferol. A Certificate of Analysis was obtained from Analytical Research Laboratories (Oklahoma City, OK) to validate capsule content potency of both the powder and the oil cholecalciferol capsules. The powder capsule was found to contain 91.3% of the stated amount of vitamin D₃, and the oil capsule was found to contain 95% of the stated amount of vitamin D₃. Blood was drawn by intravenous (IV) catheter at baseline (time 0) and 12, 24, and 48 hours after cholecalciferol dosing.

Patients were instructed to take their normal or current prescription dose of pancreatic enzymes as well as a meal or nutrition supplement just prior to dosing. Not all time points were available on all patients; results of the study are reported only for participants who completed at least 0-, 12-, and 24-hour time points. A floor nurse, independent of the study investigators, directly observed the patients taking the study drug and enzymes to confirm adherence with the study protocol.
Analysis of Serum Vitamin D₃, Plasma 25(OH)D, and Parathyroid Hormones

Serum vitamin D₃ (serum D₃) was measured with liquid chromatography–mass spectrometry (Heartland Assays, Ames, IA). Peak absorption of serum D₃ was assessed using the 12-hour time point based on 2 preceding published recommendations by Lo et al.⁶ and Farraye et al.¹⁵ The AUC for serum D₃ over all time points, calculated using the trapezoidal method,¹⁶ was also assessed as an indicator of absorption, as preceded by Lark et al.⁴ A higher 12-hour serum D₃ or higher AUC reflects greater vitamin D₃ absorption.⁶,¹⁵ Plasma 25(OH)D and plasma parathyroid hormone (PTH) were measured with an automated chemiluminescence assay (iSYS System; Immunodiagnostic Systems, Gaithersburg, MD). Quality assurance of the plasma 25(OH)D measurements was monitored by participation in the vitamin D external quality assessment scheme (DEQAS) program. To minimize interassay variability, all samples were analyzed in 1 batch and run with controls of known concentrations.

Statistical Analysis and Power

Descriptive statistics were performed and reported as a percentage or median (interquartile range [IQR]). The Shapiro-Wilk test was conducted to test for sample normality, and those deviating from a normal distribution (baseline serum D₃) were log₁₀-transformed for statistical analyses. Vehicle (oil vs powder) group differences in baseline demographics were analyzed using Fisher exact tests for categorical variables and Student t tests for continuous variables. Student t tests were used to examine vehicle group differences in the AUC for serum D₃ over 48 hours and at the individual 12-hour time point. Two-way mixed-model repeated-measures analysis of variance (ANOVA) was used to test for differences in serum D₃ and plasma 25(OH)D by group, over time, and in the group-by-time interactions. Post hoc treatment and individual time responses were analyzed using Tukey’s t tests. As this is a novel pilot study and since there were no previously published trials from which to draw power calculations, a formal power analysis was not conducted. We aimed to recruit 12–24 patients for this pilot study to establish feasibility and to produce needed preliminary data for a future, adequately powered, robust clinical trial in the event we were unable to reject the null hypothesis. Statistical analyses were performed with JMP Pro 10.0.0 (SAS Institute, Cary, NC) using 2-sided tests with a 5% significance level.

Results

Patient Demographics

A CONSORT (Consolidated Standards of Reporting Trials) diagram of study enrollment is provided in Figure 1. A total of 17 participants were randomized to receive 100,000 IU of cholecalciferol in either an oil or a powder form. One participant withdrew from the study prior to completing all crucial time points and was therefore excluded from the final analysis. A second participant was excluded from the final analysis due to an inability to acquire an adequate blood sample at the 12-hour time point, and thus 15 patients were included in the final analysis (n = 6 in powder group, n = 9 in oil group).

Baseline demographic and clinical characteristics are presented in Table 1. The demographics for each group are approximately evenly distributed with no significant
differences between oil or powder vehicle groups. The median (IQR) age of the group was 23.7 (19.9–33.2) years, approximately 50% were female, and 88% were of white ethnicity. One participant was of African American descent and 1 of East Asian descent. The median (IQR) BMI was 19.9 (18.6–22.6) kg/m². Only 2 participants were not on a pancreatic enzyme regimen, and 29% were currently prescribed a vitamin D supplement. Three patients had CF-related diabetes. Finally, most participants (75%, n = 12) had baseline plasma 25(OH)D in the vitamin D insufficient range (<30 ng/mL), and 8 patients (66%) had 25(OH)D in the vitamin D deficient range (<20 ng/mL). The median (IQR) FEV1 was 63% (37%–80%) of predicted.

**Serum Cholecalciferol (D₃) Absorption by Group**

The 12-hour serum D₃ concentration was significantly higher in the powder group compared with the oil group (144.2 ± 29.1 ng/mL vs 79.9 ± 33.1 ng/mL, P = .002; Figure 2A). The AUC (Figure 2B) for serum D₃ was also higher in the powder group compared with the oil group (3256.5 ± 285.5 ng·h/mL vs 2393.73 ± 233.1 ng·h/mL, P = .036). Mixed-model repeated-measures ANOVA indicated a significant time effect (P< .001), but the group and group-by-time interaction effects were not statistically significant (Pgroup = .38, Pgroup*time = .21).

**Plasma 25(OH)D and PTH by Time and Group**

Two-way repeated-measures ANOVA analyses (Figure 3) indicated that plasma 25(OH)D increased significantly by time (Ptime = .006), although the group effect and the group-by-time interaction were not different (Pgroup = .35, Pgroup*time = .30). There were no significant changes in PTH measurements (Figure 4) between baseline and 24 hours for either the powder or the oil group (P = .19).

**Discussion**

This pilot study examined the pharmacokinetic absorption of 2 different vehicle substances for cholecalciferol supplements in adults with CF. Pancreatic enzymes and bile are the primary conduits for the absorption of fats and fat-soluble vitamins, and it is well established that dietary fat aids the intestinal absorption of vitamin D. In CF, pancreatic scarring causes limited release of digestive enzymes into the small intestine, decreasing the absorption potential of all fats and fat-soluble vitamins. Although routine pancreatic enzymes replace this deficit, people with CF still exhibit malabsorption compared with their non-CF counterparts when consuming vitamin D with oils. In our study, we found that a cholecalciferol supplement prepared in a water-soluble powder vehicle was more efficiently absorbed than an oil preparation in patients with CF.

Patients of the study were largely vitamin D insufficient and were enrolled in the study during a hospital admission. Reason for hospital admission in the study was primarily to initiate antibiotic treatment for lung infections. Study exclusions were set to ensure that the patient did not currently have symptoms that might result in excretion of vitamin D₃ or inhibit hepatic hydroxylation to 25(OH)D beyond expected CF malabsorption. Both groups likely had vitamin D insufficiency due to decreased sun exposure and poor nutrition intake.
of vitamin D prior to hospitalization. Indeed, patients with CF who are admitted with pulmonary exacerbation have lower vitamin D status than those without pulmonary exacerbation.\(^5\)

This is the first trial to directly compare the differences in vitamin D absorption between a powder-based and an oil-based vehicle in patients with CF. There are few prior studies comparing vitamin D\(_3\) absorption from the gut based on vehicle alone.\(^7\) A systematic review of clinical trials evaluating different vitamin D vehicles identified 4 studies comparing oil, cellulose/lactose, and ethanol and evaluated their efficiency to improve vitamin D status in healthy participants.\(^11\) In their literature review, the authors concluded that oil was the most efficacious vehicle substance for healthy individuals, although the methods used in the studies using oil were inconsistent and were studied in patients without fat malabsorption.\(^11\)

Our study showed a significant rise at 12 hours in serum D\(_3\) in response to a cholecalciferol supplement contained in a powder vehicle compared with a cholecalciferol supplement contained in an oil vehicle in patients with CF. Thus, in contrast to previous suggestions in healthy individuals, our data suggest that patients with CF may have better absorption of vitamin D contained in a powder-based vehicle, as opposed to oil.

Previous studies have examined vitamin D absorption in patients with intestinal malabsorption and demonstrated that peak vitamin D absorption occurs at approximately 12 hours following supplementation.\(^6,15\) Lo et al\(^6\) developed an oral challenge test quantifying the difference in vitamin D bioavailability between healthy controls and patients with fat malabsorption syndromes using a 50,000-IU bolus dose of D\(_2\) and found that serum D\(_2\) began to rise 4 hours after ingestion and reached a peak at 12 hours after ingestion. Farraye et al\(^15\) confirmed a 12-hour peak in serum D\(_2\) with vitamin D supplementation in patients with Crohn’s disease.\(^15\) This 12-hour time point, in addition to total AUC for serum D\(_3\), was the primary end point for this study and was used as an indicator of vitamin absorption to show superiority of a powder-based vs oil-based vehicle in patients with CF.\(^14\) Notably, serum D\(_3\) concentrations did not differ between groups after 48 hours, and levels returned to baseline values. Cholecalciferol has a half-life of approximately 24 hours, explaining the decrease in serum D\(_3\) by 48 hours.\(^4\) The clinical implications for greater cholecalciferol absorption by 12 hours are yet to be determined with longer follow-up.

In our study, there was a similar rise of serum 25(OH)D in both groups from baseline to 24 hours. Interestingly, and although not statistically significant and not the primary end point for this study, the powder group had higher plasma 25(OH)D levels toward the sufficiency range than the oil group (31.3 ± 4.2 ng/mL and 22.9 ± 3.4 ng/mL, respectively). Peak plasma 25(OH)D concentrations, however, are usually not reached until 48–72 hours following supplementation, and thus we cannot fully determine the impact of the vehicle on serum 25(OH)D concentrations.\(^4\) Future head-to-head studies of cholecalciferol supplementation in a powder vs oil form with a longer period of follow-up are needed to determine the impact of vehicle on vitamin D status.

Our findings may explain why there have been differences reported in the literature regarding the bioavailability of vitamin D\(_2\) (ergocalciferol) and D\(_3\) in CF.\(^18–21\) Several studies have compared differences in the serum 25(OH)D response to oral vitamin D\(_2\) and
D₃ supplementation; however, the vehicles used in these studies were either primarily oil based or did not control for the type of vehicle when comparing vitamin D₂ and D₃.⁰,¹⁸,¹⁹,¹⁷,²² Conversely, several clinical trials supplementing vitamin D₃ have mainly employed powder vehicles (comprising lactose, cellulose, and magnesium stearate).¹¹ Khazai et al found that serum 25(OH)D increased significantly via a powder-based bolus of cholecalciferol compared with an oil-based bolus of ergocalciferol. The vehicles used, therefore, may have presented as possible confounders in previous pharmacokinetic studies. The Cystic Fibrosis Foundation recommends the use of vitamin D₃ for supplement use in CF due to its greater pharmacokinetic potency; however, the more efficient absorption of vitamin D₃ (as opposed to vitamin D₂) may have been due to the differences in the vehicle substance.⁷,¹⁰

**Strengths and Limitations**

Strengths of this study include the randomized controlled design and direct observation of the patient during ingestion of the study drug. To our knowledge, this is the first trial to measure a head-to-head comparison of 2 vehicles of cholecalciferol in an adult CF population. The study was limited by its small sample size and in its ability to assess long-term effectiveness of each vehicle due to a short collection period of 48 hours; however, our primary objective in this pilot study was to measure short-term absorption of cholecalciferol to determine vehicle efficacy. Finally, this study population was recruited during an inpatient hospital admission, and the overall health status of study patients was considered “poor.” It is unknown the extent to which CF acute illness affects metabolic processes such as nutrient absorption.

**Conclusions**

In this randomized, double-blinded, controlled pilot trial, a vitamin D₃ supplement had better absorption contained in a powder vehicle compared with supplements contained in an oil vehicle. This is the first clinical trial to evaluate such a direct vehicle substance of vitamin D₃ absorption. These findings may also explain some of the differences in efficacy of different vitamin D supplements in the CF population. The new information should provide additional guidance for clinicians when deciding on the vitamin D supplement to use in patients with CF. Additional research is still needed to determine if improved efficacy of vitamin D absorption leads to better long-term vitamin D status in the CF population.

**Acknowledgments**

Financial disclosure: This work was supported by grants from the Cystic Fibrosis Foundation (HERMES14H0 and TANGPR11A0) and the National Center for Advancing Translational Sciences of the and National Institutes of Health (K01 DK102851, UL1 TR000454).

**References**


Clinical Relevancy Statement

Patients with cystic fibrosis have fat malabsorption, increasing the risk of vitamin D deficiency, which is commonly treated with oral supplementation with vitamin D. The supplements of vitamin D contain either oil-based or powder-based vehicles. This study demonstrates that an oil-based vitamin D supplement is not as well absorbed as a powder-based supplement. These findings are clinically relevant to physicians, pharmacists, nurses, and dietitians caring for patients with cystic fibrosis.
Figure 1.
Flow diagram of participant enrollment. Patients with cystic fibrosis (n = 37) were screened for participation in the study. Recruitment took place over 1.25 years (January 2013–March 2014). Seventeen patients were enrolled and randomly assigned to receive either a powder or an oil vehicle of vitamin D₃. One patient did not complete the intervention, and 1 patient was excluded due to inadequate sample collection.
Figure 2.
The serum cholecalciferol response to a bolus dose of vitamin D₃. Box and whisker plots for serum levels of (A) cholecalciferol at 12 hours (*P = .002). (B) The area under the curve (AUC) for serum cholecalciferol (3256.5 ± 285.5 ng·h/mL vs 2393.73 ± 233.1 ng·h/mL, *P = .036).
Figure 3.
Plasma 25-hydroxyvitamin D (25(OH)D) concentrations comparing an oil vs powder vehicle in adults with cystic fibrosis. The plasma 25(OH)D concentrations rose in both groups over time compared with baseline. There was a significant time effect from baseline to 24 hours postdose (*P = .0062) with no difference between groups.
Figure 4.
Changes in parathyroid hormone over time. There was no significant change in parathyroid hormone for group, time, or group*time ($P = .190$). Time effect measures from baseline to 24 hours.
### Table 1

**Participant Demographics.**

<table>
<thead>
<tr>
<th>Demographic</th>
<th>Powder (n = 6)</th>
<th>Oil (n = 9)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>24.9 (20.0–33.2)</td>
<td>23.1 (19.5–33.2)</td>
<td>.88</td>
</tr>
<tr>
<td>Female sex</td>
<td>83.3</td>
<td>33.3</td>
<td>.11</td>
</tr>
<tr>
<td>White ethnicity</td>
<td>66.7</td>
<td>100.0</td>
<td>.14</td>
</tr>
<tr>
<td>Smoking status: never smoked</td>
<td>100</td>
<td>88.9</td>
<td>1.00</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>19.5 (17.8–21.3)</td>
<td>19.9 (18.7–25.5)</td>
<td>.35</td>
</tr>
<tr>
<td>Supplemented enzymes</td>
<td>83.3</td>
<td>88.9</td>
<td>1.00</td>
</tr>
<tr>
<td>Vitamin D supplements</td>
<td>0</td>
<td>44.4</td>
<td>.10</td>
</tr>
<tr>
<td>HbA1c</td>
<td>5.9 (5.2–6.3)</td>
<td>5.9 (5.6–6.4)</td>
<td>.53</td>
</tr>
<tr>
<td>Plasma total 25(OH)D, ng/mL</td>
<td>25.0 (11.2–36.8)</td>
<td>17.2 (9.8–26.9)</td>
<td>.38</td>
</tr>
<tr>
<td>Serum cholecalciferol, ng/mL</td>
<td>3.9 (2.1–7.6)</td>
<td>4.2 (1–7.5)</td>
<td>.98</td>
</tr>
<tr>
<td>Serum parathyroid hormone, pg/mL</td>
<td>27.4 (19.6–39.7)</td>
<td>34.8 (22.3–55.6)</td>
<td>.43</td>
</tr>
<tr>
<td>FEV1</td>
<td>64.5 (47.0–79.8)</td>
<td>54.0 (25.0–82.5)</td>
<td>.58</td>
</tr>
</tbody>
</table>

BMI, body mass index; FEV1, forced expiratory volume in 1 second; HbA1c, glycated hemoglobin; 25(OH)D, 25-hydroxyvitamin D.

\(^a\)Values reported as percentage or median (interquartile range). Statistical differences were determined with Fisher exact tests for categorical variables and t tests for continuous variables.

\(^b\) Log \(_{10}\)-transformed for statistical analysis.